1921
Volume 98, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Yellow fever (YF) is a viral disease transmitted by mosquitoes and endemic mostly in South America and Africa with 20–50% fatality. All current licensed YF vaccines, including YF-Vax (Sanofi-Pasteur, Lyon, France) and 17DD-YFV (Bio-Manguinhos, Rio de Janeiro, Brazil), are based on live attenuated virus produced in hens’ eggs and have been widely used. The YF vaccines are considered safe and highly effective. However, a recent increase in demand for YF vaccines and reports of rare cases of YF vaccine-associated fatal adverse events have provoked interest in developing a safer YF vaccine that can be easily scaled up to meet this increased global demand. To this point, we have engineered the YF virus envelope protein (YFE) and transiently expressed it in as a stand-alone protein (YFE) or as fusion to the bacterial enzyme lichenase (YFE-LicKM). Immunogenicity and challenge studies in mice demonstrated that both YFE and YFE-LicKM elicited virus neutralizing (VN) antibodies and protected over 70% of mice from lethal challenge infection. Furthermore, these two YFE-based vaccine candidates induced VN antibody responses with high serum avidity in nonhuman primates and these VN antibody responses were further enhanced after challenge infection with the 17DD strain of YF virus. These results demonstrate partial protective efficacy in mice of YFE-based subunit vaccines expressed in . However, their efficacy is inferior to that of the live attenuated 17DD vaccine, indicating that formulation development, such as incorporating a more suitable adjuvant, may be required for product development.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.16-0293
2017-12-11
2019-04-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/2/tpmd160293.html?itemId=/content/journals/10.4269/ajtmh.16-0293&mimeType=html&fmt=ahah

References

  1. WHO, 2016. Yellow Fever Fact Sheet. Updated May 2016. Available at: http://www.who.int/mediacentre/factsheets/fs100/en/. Accessed February 2017.
  2. WHO, 2017. WHO Prequalified Vaccines. Available at: https://extranet.who.int/gavi/PQ_Web/. Accessed February 2017.
  3. Sanofi Pasteur, 2016. Yellow Fever Vaccine YF-VAX®. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142831.pdf. Accessed February 2017. [Google Scholar]
  4. Barrett ADT, , 2016. Yellow fever in Angola and beyond—the problem of vaccine supply and demand. N Engl J Med 375: 301303. [Google Scholar]
  5. Martins RM, 2013. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother 9: 879888. [Google Scholar]
  6. Camacho LA, , 2008. Yellow fever and public health in Brazil. Cad Saude Publica 24: 482483. [Google Scholar]
  7. Campi-Azevedo AC, 2014. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. BMC Infect Dis 14: 391. [Google Scholar]
  8. Martins Rde M, 2014. Adverse events following yellow fever immunization: report and analysis of 67 neurological cases in Brazil. Vaccine 32: 66766682. [Google Scholar]
  9. Monath TP, , 2012. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 11: 427448. [Google Scholar]
  10. Seligman SJ, , 2014. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine 32: 57695775. [Google Scholar]
  11. Gubler DJ, Kuno G, Markoff L, , 2007. Flaviviruses. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, ed. Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins, 11531252.
  12. Kaufmann B, Rossmann MG, , 2011. Molecular mechanisms involved in the early steps of flavivirus cell entry. Microbes Infect 13: 19. [Google Scholar]
  13. Smit JM, Moesker B, Rodenhuis-Zybert I, Wilschut J, , 2011. Flavivirus cell entry and membrane fusion. Viruses 3: 160171. [Google Scholar]
  14. Stiasny K, Heinz FX, , 2006. Flavivirus membrane fusion. J Gen Virol 87: 27552766. [Google Scholar]
  15. Stiasny K, Fritz R, Pangerl K, Heinz FX, , 2011. Molecular mechanisms of flavivirus membrane fusion. Amino Acids 41: 11591163. [Google Scholar]
  16. Pierson TC, Diamond MS, , 2008. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 10: e12. [Google Scholar]
  17. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS, , 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4: 229238. [Google Scholar]
  18. Desprès P, Cahour A, Wychowski C, Girard M, Bouloy M, , 1988. Expression of the yellow fever virus envelope protein using hybrid SV40/yellow fever viruses. Ann Inst Pasteur Virol 139: 5967. [Google Scholar]
  19. Desprès P, Girard M, Bouloy M, , 1991. Characterization of yellow fever virus proteins E and NS1 expressed in Vero and Spodoptera frugiperda cells. J Gen Virol 72: 13311342. [Google Scholar]
  20. Ruiz-Linares A, Cahour A, Desprès P, Girard M, Bouloy M, , 1989. Processing of yellow fever virus polyprotein: role of cellular proteases in maturation of the structural proteins. J Virol 63: 41994209. [Google Scholar]
  21. Shiu SY, Morikawa S, Buckley A, Higgs S, Karunakarannair V, Blachere C, Gould EA, , 1991. 17D yellow fever vaccine virus envelope protein expressed by recombinant baculovirus is antigenically indistinguishable from authentic viral protein. J Gen Virol 72: 14511454. [Google Scholar]
  22. Barros MC, Galasso TG, Chaib AJ, Degallier N, Nagata T, Ribeiro BM, , 2011. Yellow fever virus envelope protein expressed in insect cells is capable of syncytium formation in lepidopteran cells and could be used for immunodetection of YFV in human sera. Virol J 8: 261. [Google Scholar]
  23. Mett V, Farrance CE, Green BJ, Yusibov V, , 2008. Plants as biofactories. Biologicals 36: 354358. [Google Scholar]
  24. Rybicki EP, , 2010. Plant-made vaccines for humans and animals. Plant Biotechnol J 8: 620637. [Google Scholar]
  25. Yusibov V, Streatfield SJ, Kushnir N, , 2011. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin 7: 313321. [Google Scholar]
  26. Gomord V, Faye L, , 2004. Posttranslational modification of therapeutic proteins in plants. Curr Opin Plant Biol 7: 171181. [Google Scholar]
  27. Bosch D, Castilho A, Loos A, Schots A, Steinkellner H, , 2013. N-glycosylation of plant-produced recombinant proteins. Curr Pharm Des 19: 55035512. [Google Scholar]
  28. Gomord V, Fitchette AC, Menu-Bouaouiche L, Saint-Jore-Dupas C, Plasson C, Michaud D, Faye L, , 2010. Plant-specific glycosylation patterns in the context of therapeutic protein production. Plant Biotechnol J 8: 564587. [Google Scholar]
  29. Webster DE, Thomas MC, , 2012. Post-translational modification of plant-made foreign proteins; glycosylation and beyond. Biotechnol Adv 30: 410418. [Google Scholar]
  30. Mamedov T, Ghosh A, Jones RM, Mett V, Farrance CE, Musiychuk K, Horsey A, Yusibov V, , 2012. Production of non-glycosylated recombinant proteins in Nicotiana benthamiana plants by co-expressing bacterial PNGase F. Plant Biotechnol J 10: 773782. [Google Scholar]
  31. Shaaltiel Y, 2007. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol J 5: 579590. [Google Scholar]
  32. Traynor K, , 2012. Taliglucerase alfa approved for Gaucher disease. Am J Health Syst Pharm 69: 1009. [Google Scholar]
  33. Yusibov V, Streatfield SJ, Kushnir N, Roy G, Padmanaban A, , 2013. Hybrid viral vectors for vaccine and antibody production in plants. Curr Pharm Des 19: 55745586. [Google Scholar]
  34. Yusibov V, Rabindran S, , 2008. Recent progress in the development of plant derived vaccines. Expert Rev Vaccines 7: 11731183. [Google Scholar]
  35. Musiychuk K, 2007. A launch vector for the production of vaccine antigens in plants. Influenza Other Respir Viruses 1: 1925. [Google Scholar]
  36. Shoji Y, 2011. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin 7 (Suppl): 4150. [Google Scholar]
  37. Chichester JA, Manceva SD, Rhee A, Coffin MV, Musiychuk K, Mett V, Shamloul M, Norikane J, Streatfield SJ, Yusibov V, , 2013. A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores. Hum Vaccin Immunother 9: 544552. [Google Scholar]
  38. Chichester JA, Musiychuk K, Farrance CE, Mett V, Lyons J, Yusibov V, , 2009. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. Vaccine 27: 34713474. [Google Scholar]
  39. Mett V, Lyons J, Musiychuk K, Chichester JA, Brasil T, Couch R, Sherwood R, Palmer GA, Streatfield SJ, Yusibov V, , 2007. A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine 25: 30143017. [Google Scholar]
  40. Farrance CE, 2011. Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity. Hum Vaccin 7 (Suppl): 191198. [Google Scholar]
  41. Jones RM, 2015. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses. Hum Vaccin Immunother 11: 124132. [Google Scholar]
  42. Knapp EGL, 2010. Tubulin-based vaccine candidates to combat African animal trypanosomiasis. Am J Trop Med Hyg 83 (Suppl): 206 (American Society of Tropical Medicine and Hygene 59th Annual Meeting. Abstract 691). [Google Scholar]
  43. Chichester JA, Jones RM, Green BJ, Stow M, Miao F, Moonsammy G, Streatfield SJ, Yusibov V, , 2012. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses 4: 32273244. [Google Scholar]
  44. Cummings JF, Guerrero ML, Moon JE, Waterman P, Nielsen RK, Jefferson S, Gross FL, Hancock K, Katz JM, Yusibov V, , 2014. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults. Vaccine 32: 22512259. [Google Scholar]
  45. Chichester JA, Musiychuk K, de la Rosa P, Horsey A, Stevenson N, Ugulava N, Rabindran S, Palmer GA, Mett V, Yusibov V, , 2007. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 25: 31113114. [Google Scholar]
  46. Mett V, 2008. A plant-produced influenza subunit vaccine protects ferrets against virus challenge. Influenza Other Respir Viruses 2: 3340. [Google Scholar]
  47. Shoji Y, 2009. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. Vaccine 27: 10871092. [Google Scholar]
  48. Shoji Y, 2008. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 26: 29302934. [Google Scholar]
  49. Shoji Y, 2009. Immunogenicity of hemagglutinin from A/Bar-headed Goose/Qinghai/1A/05 and A/Anhui/1/05 strains of H5N1 influenza viruses produced in Nicotiana benthamiana plants. Vaccine 27: 34673470. [Google Scholar]
  50. Shamloul M, Trusa J, Mett V, Yusibov V, , 2014. Optimization and utilization of Agrobacterium-mediated transient protein production in Nicotiana. J Vis Exp 86: e51204. [Google Scholar]
  51. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T, , 1995. How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4: 24112423. [Google Scholar]
  52. Niedrig M, Lademann M, Emmerich P, Lafrenz M, , 1999. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 4: 867871. [Google Scholar]
  53. Simoes M, Camacho LA, Yamamura AM, Miranda EH, Cajaraville AC, da Silva Freire M, , 2012. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals 40: 399404. [Google Scholar]
  54. Caufour PS, Motta MC, Yamamura AM, Vazquez S, Ferreira II, Jabor AV, Bonaldo MC, Freire MS, Galler R, , 2001. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res 79: 114. [Google Scholar]
  55. Trindade GF, Marchevsky RS, Fillipis AM, Nogueira RM, Bonaldo MC, Acero PC, Caride E, Freire MS, Galler R, , 2008. Limited replication of yellow fever 17DD and 17D-dengue recombinant viruses in rhesus monkeys. An Acad Bras Cienc 80: 311321. [Google Scholar]
  56. Matos DC, Silva AM, Neves PC, Martins RM, Homma A, Marcovistz R, , 2009. Pattern of functional antibody activity against Haemophilus influenzae type B (Hib) in infants immunized with diphtheria-tetanus-pertussis/Hib Brazilian combination vaccine. Braz J Med Biol Res 42: 12421247. [Google Scholar]
  57. Santos AP, Matos DC, Bertho AL, Mendonca SC, Marcovistz R, , 2008. Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. Cytokine 42: 152155. [Google Scholar]
  58. Dowd KA, Pierson TC, , 2011. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 411: 306315. [Google Scholar]
  59. Monath TP, 2010. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28: 38273840. [Google Scholar]
  60. Liu T, Matsuguchi T, Tsuboi N, Yajima T, Yoshikai Y, , 2002. Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice. Infect Immun 70: 66386645. [Google Scholar]
  61. Schulte S, Sukhova GK, Libby P, , 2008. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol 172: 15001508. [Google Scholar]
  62. Stiasny K, Aberle JH, Keller M, Grubeck-Loebenstein B, Heinz FX, , 2012. Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS One 7: e34145. [Google Scholar]
  63. Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, Harris E, , 2013. Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis 7: e2274. [Google Scholar]
  64. Barba-Spaeth G, Longman RS, Albert ML, Rice CM, , 2005. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 202: 11791184. [Google Scholar]
  65. Luiza-Silva M, 2011. Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. J Infect Dis 204: 873883. [Google Scholar]
  66. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B, , 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203: 413424. [Google Scholar]
  67. Kohler S, Bethke N, Bothe M, Sommerick S, Frentsch M, Romagnani C, Niedrig M, Thiel A, , 2012. The early cellular signatures of protective immunity induced by live viral vaccination. Eur J Immunol 42: 23632373. [Google Scholar]
  68. Neves PC, Rudersdorf RA, Galler R, Bonaldo MC, de Santana MG, Mudd PA, Martins MA, Rakasz EG, Wilson NA, Watkins DI, , 2010. CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-gamma at 5–7 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses. Vaccine 28: 81838188. [Google Scholar]
  69. Neves PC, Santos JR, Tubarao LN, Bonaldo MC, Galler R, , 2013. Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses. PLoS One 8: e81953. [Google Scholar]
  70. Liu T, Chambers TJ, , 2001. Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes. J Virol 75: 21072118. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0293
Loading
/content/journals/10.4269/ajtmh.16-0293
Loading

Data & Media loading...

  • Received : 14 Apr 2016
  • Accepted : 28 Sep 2017
  • Published online : 11 Dec 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error